These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33819969)

  • 1. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].
    Zhang T; Li B
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
    Breimer LH; Nousios P; Olsson L; Brunnström H
    Scand J Clin Lab Invest; 2020 Sep; 80(5):360-369. PubMed ID: 32238062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)].
    Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Mhanna L; Guibert N; Milia J; Mazieres J
    Curr Treat Options Oncol; 2019 Jun; 20(7):60. PubMed ID: 31172347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in advanced non-small-cell lung cancer with
    Liu F; Yuan X; Jiang J; Chu Q
    Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation].
    Li T; Li J
    Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):19-24. PubMed ID: 33478186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to 
Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
    Li J; Yao X; Qiu L; Zhang R; Wang G
    Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):392-399. PubMed ID: 37316449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
    Wang L; Ren Z; Yu B; Tang J
    J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.
    Otano I; Ucero AC; Zugazagoitia J; Paz-Ares L
    Nat Rev Clin Oncol; 2023 Mar; 20(3):143-159. PubMed ID: 36639452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
    Pasello G; Pavan A; Attili I; Bortolami A; Bonanno L; Menis J; Conte P; Guarneri V
    Cancer Treat Rev; 2020 Jul; 87():102031. PubMed ID: 32446182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
    Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
    Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.